Gilead announces new data on Biktarvy for the treatment of HIV in Black Americans

This article was originally published here

These data presented at IDWeek 2020 show that switching from a standard regimen of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent to Biktarvy is an

The post Gilead announces new data on Biktarvy for the treatment of HIV in Black Americans appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply